2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purines as antiviral agents
Compounds which are active against viruses have the following Formulas: wherein B is 2-aminopurine-9-yl, which may be unsubstituted or substituted in the 6 position with NHR 1 , OR 2 , or SR 3 ; R 1 is selected from the group consisting of alkyl, alkenyl, alkynyl, and C 4-18 cycloalkyl, any of which may be optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl; R 2 is selected from the group consisting of C 2-18 alkyl, alkenyl, alkynyl, and cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl, and aryl; and R 3 is selected from the group consisting of alkyl, alkenyl, alkynyl, and cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl.
1. A method of treating a mammal infected with a virus selected from the group consisting of a cytomegalovirus (CMV), herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2), human herpes virus-6 (HHV-6), human herpes virus-7 (HHV-7), human herpes virus-8 (HHV-8), and hepatitis B virus (HBV) comprising the step of administering to said mammal an effective amount of:
a compound having Formula 1 or Formula 2:
wherein B is 2-aminopurine-9-yl, unsubstituted or substituted at the 6 position with NHR 1 , OR 2 , or SR 3 ;
R 1 is selected from the group consisting of alkenyl, alkynyl, and benzyl, any of which may be optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
R 2 is selected from the group consisting of alkenyl, alkynyl, and cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl, and aryl; and
R 3 is selected from the group consisting of alkyl, alkenyl, alkynyl, and cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
or
a compound having Formula 3 or Formula 4:
wherein X is O;
R 1 and R 2 are alkyl or aryl; or R 1 X or R 2 X is an amino acid residue with X as NH;
B is 2-aminopurine-9-yl, which is unsubstituted or substituted at the 6 position with NHR 4 , OR 5 , or SR 6 ;
R 4 is selected from the group consisting of alkenyl, and alkynyl, any of which may be optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
R 5 is selected from the group consisting of alkenyl, alkynyl, and cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
R 6 is selected from the group consisting of alkyl, alkenyl, alkynyl, and cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
or a combination thereof.
2. The method of claim 1 , wherein B is substituted at the 6 position with NHR 1 , OR 2 , or SR 3 , wherein:
R 1 is selected from the group consisting of C 3 -C 8 alkenyl, and C 3 -C 8 alkynyl, any of which may be optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
R 2 is selected from the group consisting of C 3 -C 8 alkenyl, C 3 -C 8 alkynyl, and C 3 -C 10 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
and
R 3 is selected from the group consisting of C 2-8 alkyl, C 3 -C 8 alkenyl, C 3 -C 8 alkynyl, and C 3-10 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl.
3. The method of claim 1 , wherein B is 2-aminopurine-9-yl, which is substituted in the 6 position with NHR 1 , OR 2 , or SR 3 , wherein:
R 1 is selected from the group consisting of C 3 -C 6 alkenyl, and C 3 -C 6 alkynyl, any of which may be optionally substituted with one or more members of the group consisting cycloalkyl, heterocyclyl and aryl;
R 2 is selected from the group consisting of C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, and C 3-8 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of cycloalkyl, heterocyclyl, and aryl; and
R 3 is selected from the group consisting of C 2-6 alkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, and C 3-8 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl.
4. The method of claim 1 , wherein the compound is selected from the group consisting of (Z,S)-(+)-2-amino-6-allylamino-9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino-6-propargylamino-9-[(2-hydroxymethyl)cyclo-propylidenemethyl]purine; (Z,S)-(+)-2-amino-6-isopropylamino-9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino-6-benzylamino 9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino-6-cyclohexylamino-9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino-6-(2-hydroxyl)ethylamino-9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino-6-allyloxy-9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino-6-cyclopropylmethoxy-9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino-6-propylthio 9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino6-pentylthio-9-[(2-hydroxymethyl)cyclopropylidene-methyl]purine; and (Z,S)-(+)-2-amino-9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine.
5. The method of claim 1 , wherein B is 2-aminopurine-9-yl, which is substituted at the 6 position with NHR 4 , OR 5 , or SR 6 , wherein:
R 4 is selected from the group consisting of C 3 -C 8 alkenyl, and C 3 -C 8 alkynyl, any of which may be optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
R 5 is selected from the group consisting of C 3 -C 8 alkenyl, C 3 -C 8 alkynyl, and C 3-10 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl, and aryl; and
R 6 is selected from the group consisting of C 2 alkyl, C 3 -C 8 alkenyl, C 3 -C 8 alkynyl, and C 3-10 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl.
6. The method of claim 1 , wherein B is 2-aminopurine-9-yl, which is substituted in the 6 position with NHR 4 , OR 5 , or SR 6 , wherein:
R 4 is selected from the group consisting of C 3 -C 6 alkenyl, and C 3 -C 6 alkynyl, any of which may be optionally substituted with one or more members of the group consisting cycloalkyl, heterocyclyl and aryl;
R 5 is selected from the group consisting of C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, and C 3-8 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of cycloalkyl, heterocyclyl, and aryl; and
R 6 is selected from the group consisting of C 2-6 alkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, and C 3-8 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl.
7. The method of any one of claims 1 - 6 , wherein said mammal is a human.
8. The method of any one of claims 1 - 6 , further comprising a step of administering an additional compound.
9. The method of claim 8 , wherein said additional compound is selected from the group consisting of acyclovir, ganciclovir, zidovudine, AZT, ddI, ddC, 3TC, d4T, and combinations thereof.
10. The method of claim 1 , wherein the virus is selected from the group consisting of a cytomegalovirus (CMV), herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2).
11. A method of reducing viral replication in a mammal infected with a virus selected from the group consisting of a cytomegalovirus (CMV), herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2), human herpes virus-6 (HHV-6), human herpes virus-7 (HHV-7), human herpes virus-8 (HHV-8), and hepatitis B virus (HBV) comprising the step of administering to said mammal an effective amount of:
a compound having Formula 1 or Formula 2:
wherein B is 2-aminopurine-9-yl, unsubstituted or substituted at the 6 position with NHR 1 , OR 2 , or SR 3 ;
R 1 is selected from the group consisting of alkenyl, alkynyl, and benzyl, any of which may be optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
R 2 is selected from the group consisting of alkenyl, alkynyl, and cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl, and aryl; and
R 3 is selected from the group consisting of alkyl, alkenyl, alkynyl, and cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
or
a compound having Formula 3 or Formula 4:
wherein X is O;
R 1 and R 2 are alkyl or aryl; or R 1 X or R 2 X is an amino acid residue with X as NH;
B is 2-aminopurine-9-yl, which is unsubstituted or substituted at the 6 position with NHR 4 , OR 5 , or SR 6 ;
R 4 is selected from the group consisting of alkenyl, and alkynyl, any of which may be optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
R 5 is selected from the group consisting of alkenyl, alkynyl, and cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
R 6 is selected from the group consisting of alkyl, alkenyl, alkynyl, and cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
or a combination thereof.
12. The method of claim 11 , wherein B is substituted at the 6 position with NHR 1 , OR 2 , or SR 3 , wherein:
R 1 is selected from the group consisting of C 3 -C 8 alkenyl, and C 3 -C 8 alkynyl, any of which may be optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
R 2 is selected from the group consisting of C 3 -C 8 alkenyl, C 3 -C 8 alkynyl, and C 3 -C 10 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl; and
R 3 is selected from the group consisting of C 2-8 alkyl, C 3 -C 8 alkenyl, C 3 -C 8 alkynyl, and C 3-10 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl.
13. The method of claim 11 , wherein B is 2-aminopurine-9-yl, which is substituted in the 6 position with NHR 1 , OR 2 , or SR 3 , wherein:
R 1 is selected from the group consisting of C 3 -C 6 alkenyl, and C 3 -C 6 alkynyl, any of which may be optionally substituted with one or more members of the group consisting cycloalkyl, heterocyclyl and aryl;
R 2 is selected from the group consisting of C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, and C 3-10 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of cycloalkyl, heterocyclyl, and aryl; and
R 3 is selected from the group consisting of C 2-6 alkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, and C 3-8 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl.
14. The method of claim 11 , wherein the compound is selected from the group consisting of (Z,S)-(+)-2-amino-6-allylamino-9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino-6-propargylamino-9-[(2-hydroxymethyl)cyclo-propylidenemethyl]purine; (Z,S)-(+)-2-amino-6-isopropylamino-9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino-6-benzylamino 9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino-6-cyclohexylamino-9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino-6-(2-hydroxyl)ethylamino-9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino-6-allyloxy-9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino-6-cyclopropylmethoxy-9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino-6-propylthio 9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine; (Z,S)-(+)-2-amino6-pentylthio-9-[(2-hydroxymethyl)cyclopropylidene-methyl]purine; and (Z,S)-(+)-2-amino-9-[(2-hydroxymethyl)cyclopropylidenemethyl]purine.
15. The method of claim 11 , wherein B is 2-aminopurine-9-yl, which is substituted at the 6 position with NHR 4 , OR 5 , or SR 6 , wherein:
R 4 is selected from the group consisting of C 3 -C 8 alkenyl, and C 3 -C 8 alkynyl, any of which may be optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl;
R 5 is selected from the group consisting of C 3 -C 8 alkenyl, C 3 -C 8 alkynyl, and C 3-10 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl, and aryl; and
R 6 is selected from the group consisting of C 2 alkyl, C 3 -C 8 alkenyl, C 3 -C 8 alkynyl, and C 3-10 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl.
16. The method of claim 11 , wherein B is 2-aminopurine-9-yl, which is substituted in the 6 position with NHR 4 , OR 5 , or SR 6 , wherein:
R 4 is selected from the group consisting of C 3 -C 6 alkenyl, and C 3 -C 6 alkynyl, any of which may be optionally substituted with one or more members of the group consisting cycloalkyl, heterocyclyl and aryl;
R 5 is selected from the group consisting of C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, and C 3-8 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of cycloalkyl, heterocyclyl, and aryl; and
R 6 is selected from the group consisting of C 2-6 alkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, and C 3-8 cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl.
17. The method of any one of claims 11 - 16 , wherein said mammal is a human.
18. The method of any one of claims 11 - 16 , further comprising a step of administering an additional compound.
19. The method of claim 18 , wherein said additional compound is selected from the group consisting of acyclovir, ganciclovir, zidovudine, AZT, ddI, ddC, 3TC, d4T, and combinations thereof.